Fennec Pharmaceuticals director proposes $240K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fennec Pharmaceuticals Inc. (FENC) director Marco Brughera, who signed as Marco Maria Brughera, gave notice of a proposed sale of 20,000 common shares, with an aggregate market value of $240,000.00 and an approximate sale date of November 13, 2026. The shares were acquired from the issuer on November 13, 2026 through a stock option exercise, with cash listed as the payment method. The notice reports 35,305,117 common shares outstanding and a September 15, 2026 sale of 15,545 common shares for gross proceeds of $160,069.97 during the prior three months. It lists June 16, 2026 as the plan adoption or instruction date, if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which broker and exchange are listed for Marco Brughera's proposed FENC sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.